profit from every $100 of sales.
$0$100
Generate Biomedicines
$12.07-3.98% today
-4.6% since Feb 23, 26
1-year low $11.211-year high $20.38
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Generate Biomedicines sold, what it kept, and what it did with the cash.
Sales went from $20.5 million in 2024 to $31.9 million in 2025, with -$203 million of profit last year.
SalesProfit
Generate Biomedicines vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Generate Biomedicines | No profit yet | ||
 BlackRock | 34.0× · Expensive | ||
 Blackstone | 49.1× · Expensive | ||
 Investor | 8.5× · Cheap | ||
 Brookfield | 70.0× · Very expensive |
AI analysis
An AI analyst reads Generate Biomedicines's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2024 | 2025 |
|---|---|---|
| 20 | 32 | |
| – | – | |
| -197 | -235 | |
| -164 | -208 | |
| -174 | -203 | |
| -2.09 | -2.18 | |
| – | – | |
| -962.6% | -737.0% | |
| -849.4% | -637.0% |
Balance sheet
| In millions of USD | 2024 | 2025 |
|---|---|---|
| Total assets | 518 | 330 |
| Cash | 176 | 122 |
| Total debt | 77 | 69 |
| Total liabilities | 953 | 953 |
| -435 | -616 | |
| 102 | 102 | |
| – | – | |
| 40.0% | 33.0% |
Cash flow
| In millions of USD | 2024 | 2025 |
|---|---|---|
| -118 | -201 | |
| 3 | 4 | |
| -121 | -204 | |
| Dividends paid | – | – |
| – | – | |
| 19 | 21 |
Valuation
- –
- –
- –
- -1.1×
- 48.9×
- –
- –
- -13.1%
- -13.0%
- 0.0%
Profitability
- 100.0%
- -737.0%
- -637.0%
- -653.7%
- -89.4%
- 42.9%
- 38.7%
- -61.5%
- -94.8%
- 704.5%
Growth
- +55.9%
- –
- −68.4%
- –
- −60.7%
Financial health
- -0.3×
- -0.11
- 20.8%
- -206.9×
- 2.85
- 2.85
- 0.10
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 667
Top 7%of 911
Bottom 11%of 939
News
3 Dividend ETFs That Could Generate Thousands of Dollars in Passive IncomeYahoo Finance · Nov 8, 2026Jensen Huang Says Nvidia's Next-Gen Vera Rubin Chips Will Generate $40 Billion in Revenue per Gigawatt, Up From $25 Billion for Grace Blackwell. What That Means for Nvidia's Growth Runway?Yahoo Finance · Nov 6, 2026All It Takes Is $5,000 Invested in Enterprise Products Partners (EPD) to Generate $300 in Annual Passive IncomeYahoo Finance · Oct 28, 2026Jensen Huang Says Nvidia's Next-Gen Vera Rubin Chips Will Generate $40 Billion in Revenue per Gigawatt, Up From $25 Billion for Grace Blackwell. What That Means for NVDA's Growth Runway.Yahoo Finance · Oct 26, 2026If You Invest $1,000 a Year in Morgan Stanley (MS) Stock, How Much Dividend Income Could It Generate Over 20 Years?Yahoo Finance · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/6Passes 4 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
44No pass
Philip Fisher
86Pass
Peter Lynch
–Not enough data
Joel Greenblatt
4No pass
Charlie Munger
87Pass
Terry Smith
85Pass
Questions about Generate Biomedicines
Is Generate Biomedicines a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Generate Biomedicines AI analysis
What does Generate Biomedicines do?
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. It is in Asset Management.
Does Generate Biomedicines pay a dividend?
No. Generate Biomedicines does not pay a dividend at the moment.
Is Generate Biomedicines stock halal?
Yes. Generate Biomedicines passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
Who are Generate Biomedicines's competitors?
The largest listed companies in the same industry are BlackRock, Blackstone, Investor and Brookfield. The peers table on this page compares their profit, growth and price with Generate Biomedicines's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.